Clinical Study

Hormone therapy protects from diabetes: the Kuopio osteoporosis risk factor and prevention study

Kati Pentti1, Marjo T Tuppurainen1,6, Risto Honkanen1,6, Lorenzo Sandini2,3, Heikki Kröger3,4, Esko Alhava5 and Seppo Saarikoski1

1Department of Obstetrics and Gynecology, Kuopio University Hospital, FIN-70211 Kuopio, Finland, 2Department of Internal Medicine, Kuopio University Hospital, Kuopio, Finland, 3Bone and Cartilage Research Unit, University of Kuopio, Kuopio, Finland, 4Department of Orthopaedics, Traumatology and Hand Surgery, Kuopio University Hospital, Kuopio, Finland, 5Department of Surgery, Institute of Clinical Medicine, Kuopio University Hospital, Kuopio, Finland and 6Research Institute of Public Health, University of Kuopio, Kuopio, Finland

(Correspondence should be addressed to K Pentti; Email: kati.pentti@fimnet.fi)

Abstract

Objectives: The purpose of this population-based prospective cohort study was to examine the effect of hormone therapy (HT) on incidence of diabetes mellitus (DM).

Design and methods: Eight thousand four hundred and eighty-three DM-free post-menopausal women aged 52–62 from the population-based Kuopio osteoporosis risk factor and prevention study were followed for 5 years from 1994–1999. Information about the use of HT and health events was obtained from three repeated questionnaires in 1989, 1994, and 1999. DM morbidity before and during the follow-up was obtained from the Registry of Specially Refunded Drugs of the Finnish Social Insurance Institution. Kaplan–Meyer survival curves and Cox’s proportional-hazards models were used to estimate the risk of incident DM in relation to the use of HT.

Results: During the follow-up, 40.8% DM-free post-menopausal women had never used HT, 27.3% women were HT past users and 31.9% women had used HT presently during the follow-up. During the follow-up, 162 incident DM cases were recorded. Compared with never users of HT, the adjusted hazard ratio of DM was 0.81 (95% confidence interval (CI) 0.57–1.16) for only past users, 0.53 (95% CI 0.24–1.15) in part-time (during the follow-up 2.5 years) users and 0.31 (95% CI 0.16–0.60) in continuous (during the follow-up 2.5–5.0 years) users of HT.

Conclusions: HT use decreases the incidence of DM in post-menopausal women.

European Journal of Endocrinology 160 979–983

Introduction

Diabetes mellitus (DM) is one of the most common chronic diseases in the world. Type 2 DM is increasingly being recognized as a critical health problem especially in middle-aged and elderly people (1). Obesity and physical inactivity are established risk factors for type 2 DM and cardiovascular comorbidities (2). It is estimated that the number of diabetic people in the world will double from 171 million in 2000 to 366 million in 2030. Globally, the prevalence of DM is similar in men and women, but it is slightly higher in men under the age of 60 and in women at older ages (3).

Recent studies have suggested that post-menopausal hormone therapy (HT) is associated with lower incidence of DM. The Heart Estrogen Progestin Replacement Study (HERS) (4) and the Women’s Health Initiative (WHI) trials (5, 6) were the first randomized controlled studies showing the positive effects of HT on DM. Primarily, HERS (4) and the WHI (5, 6) studied the effects of HT on cardiovascular disease (CVD) and there was no improvement of cardiovascular outcomes but, on the contrary, a significantly lower incidence of DM among HT users. Some (7) but not all (8, 9) observational studies have also noted a decreased incidence of DM among post-menopausal HT users.

The primary aim of this prospective 5-year study from the population-based study cohort was to examine the effects of HT on the incidence of DM in post-menopausal women.

Materials and methods

Study population

This study is a part of the Kuopio osteoporosis risk factor and prevention population-based prospective cohort study. The target population primarily consisted of the 14 220 women resident in Kuopio Province and born in 1932–41 (aged 52–62 years in 1994) to whom a postal inquiry was sent in May 1989. The study population has
been described in detail previously (10). In all, 13 100 women (92.8%) responded. The second follow-up inquiry was sent to women alive in May 1994. A total of 11 798 women responded to both inquiries. Women whose HT use in May 1994 could not be clarified were excluded (n=131). A woman was regarded as post-menopausal if ≥12 months had elapsed since her last natural menstruation or if she had undergone bilateral oophorectomy before May 1994. A total of 839 pre-menopausal women and women whose menopause could not be defined due to hysterectomy (n=1146) or to incomplete data (n=328) were also excluded from the study. Women were considered to have previous DM if they self-reported DM, present use of insulin or oral glucose-lowering medications in 1989 or 1994 and women with that information about DM before the start of follow-up according to the Registry of Specially Refunded Drugs of the Finnish Social Insurance Institution (SII; total n=282). There were 9072 post-menopausal non-diabetic women in May 1994. In total 8483 (of 9072) post-menopausal women also responded to the third follow-up inquiry in May 1999 which formed the final study population of this study.

This study was approved by the local ethics committee in 1986, 1994, and 1997.

Hormone therapy

The lifetime use of HT in years before the baseline of this study was recorded in two postal enquiries in 1989 and 1994. The duration of HT use in months for each year of follow-up from 1994–1999 was recorded by postal enquiry in 1999. Inconsistent or missing HT information was clarified by telephone interview or by additional postal enquiry. HT use was defined as use of preparations having systemic estrogentic properties, and classified in four categories as follows: never, only in the past (before baseline 1994), part-time (<2.5 years of HT use during the follow-up) and continuous (2.5–5.0 years of HT use during the follow-up). The uniformity of HT use was examined and was found to be approximately uniform throughout the follow-up.

Diabetes

New cases of established DM during the follow-up (n=162) were ascertained with the Registry of Specially Refunded Drugs of the SII. According to the National Sickness Insurance, the SII granted 100% reimbursement for drug costs in defined chronic illnesses necessitating continuous medication, like DM.

According to the National Sickness Insurance, the criteria for reimbursement of medicines in DM (ICD-9 codes 250.0–250.9 and ICD-10 codes E10–E14, E89.1) are as follows:

Examinations and diagnosis of type 1 diabetes (DM1) and type 2 diabetes (DM2) have to be made in the specialized health care unit or by a specialist physician. Owing to high prevalence of DM2, right to reimbursement can be based also upon an opinion from any physician.

I. Patient has the right to reimbursement for DM2 medication when the patient has typical symptoms of DM (polyuria, polydipsia, and glucosuria) and fasting glucose in capillary or vein blood is at least 7.0 mmol/l or in plasma blood at least 8.0 mmol/l. If the symptoms of DM are missing, DM diagnosis has to be confirmed by repeated testing.

II. Patient has the right to reimbursement for DM2 medication when the patient has used DM medication for at least 6 months and the positive effects of medication have been described. An overweight DM2 patient must undergo at least 6 months of dietary treatment before medical treatment. The medical certificate concerning DM2 must include information about the duration of diet use and its effects on weight. Furthermore, the symptoms, findings, and blood and urine glucose status and possible albuminuria, especially before medical treatment, may be described. When DM diagnosis has been made, a medical doctor will write the statement to the SII, which will then give the patient the right to reimbursement for DM (The Finnish Social Insurance Institution (Kela); http://www.kela.fi/in/internet/suomi.nsf/NET/040304095807UK?open Document). In the present study, the date of a physician’s statement for DM was used as the endpoint of DM follow-up. In all, 162 post-menopausal women had new incident DM during the follow-up.

Other variables

The inquiries included questions about gynecological history (parity, last menstruation, and menopausal symptoms) and surgery, height, weight, smoking, and chronic health disorders diagnosed by physician (with >100 different items). Present medication prescribed by a doctor was also asked in both inquiries: as well as the names of medications (including duration of use) and diseases that they were taking medications for. SII registry was used together with the inquiries in 1989 and 1994 to determine the women’s baseline status concerning the occurrence of hypertension and hypercholesterolaemia. Body mass index (BMI) was calculated as the ratio of weight in kilograms to height in square meters (kg/m²).

Statistical analysis

The statistical analyses were performed with the SPSS (INC 14.0) program. The differences in baseline characteristics between HT users (during the follow-up) and never users were tested by using ANOVA to compare the means of continuous variables and the \( \chi^2 \)-test to
Table 1 Baseline characteristics (in 1994) of the 8483 non-diabetic post-menopausal women according to the hormone therapy (HT) use.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Never (n=3463)</th>
<th>Past (n=2714)</th>
<th>Current (n=2706)</th>
<th>Total (n=8483)</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>( n ) (%)</td>
<td>3463 (40.8%)</td>
<td>2714 (32.3%)</td>
<td>2706 (31.9%)</td>
<td>8483</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age (mean, (s.d.))</td>
<td>58.1 (2.8)</td>
<td>57.7 (2.8)†</td>
<td>56.6 (2.7)†</td>
<td>57.6 (2.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BMI (kg/m², mean (s.d.))</td>
<td>27.5 (4.7)</td>
<td>27.4 (4.3)</td>
<td>25.9 (3.6)†</td>
<td>27.0 (4.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Parity (mean, (s.d.))</td>
<td>2.6 (1.7)</td>
<td>2.5 (1.6)</td>
<td>2.3 (1.4)†</td>
<td>2.5 (1.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Smoking (%)</td>
<td>18.5</td>
<td>19.5</td>
<td>18.2</td>
<td>18.9</td>
<td>0.010</td>
</tr>
<tr>
<td>Chronic hypercholesterolaemia (%)</td>
<td>24.9</td>
<td>28.2*</td>
<td>22.1*</td>
<td>24.9</td>
<td></td>
</tr>
<tr>
<td>Hysterectomy (%)</td>
<td>6.5</td>
<td>11.6*</td>
<td>20.0*</td>
<td>12.2</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Comparison of each HT group with non-users by 1994. *\( P < 0.05 \), \( \chi^2 \)-test. †\( P < 0.05 \), ANOVA.

Discussion

In the present population-based 5-year prospective cohort study on post-menopausal women, HT use significantly decreased the risk of developing DM. The risk decrease was accentuated (69%) in women who used HT more than half of the follow-up time.

Table 2 The relative risk of incident diabetes (DM) as hazard ratios with 95% confidence interval (CI) in relation to use of hormone therapy (HT) in post-menopausal women during the 5-year follow-up.

<table>
<thead>
<tr>
<th>Use of HT</th>
<th>DM (n=162)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Age-adjusted</td>
</tr>
<tr>
<td>DM (n=162)</td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>90 (1.0)</td>
</tr>
<tr>
<td>Past</td>
<td>51 (0.86)</td>
</tr>
<tr>
<td>Part-time (&lt;2.5 years)</td>
<td>8 (0.46)</td>
</tr>
<tr>
<td>Continuous (≥2.5 years)</td>
<td>13 (0.26)</td>
</tr>
</tbody>
</table>

Multivariate covariates: age, BMI (kg/m²), parity, hypertension (n/y), hypercholesterolaemia (n/y), hysterectomy (n/y) and smoking (never, ever).
The strengths of this study include its population-based nature, detailed information about HT use and careful diagnosis of incident IDDM based on the registry of specially refunded drugs of the SII. The registries in Finland have proven to be reliable (11). A limitation of our study was that baseline characteristics of current HT users had fewer risk factors than HT non-users. However, adjusting for those characteristics did not affect the results. In addition, no interactions between HT use and these factors were found. Our study did not distinguish between unopposed estrogen and combined therapy or between oral and transdermal application.

Several observational studies and RCTs have examined the role of HT use in the prevention of DM but none of those studies has found as strong a preventive effect as this study (4–7). Manson et al. (7) reported a 20% lower incidence of DM in women using HT compared with women who did not use it in the Nurse’s Health Study. In a randomized controlled trial, the HERS study (4), the corresponding decrement was 35%. Lastly, the WHI trial reported 11–17% lowered risk of DM in HT users compared with non-users (5, 6). On the other hand, the Strong Heart Study (8) reported that the risk of type 2 DM increased by 10% per year of present estrogen use, while Gabal et al. (9) did not find a statistically significant change in DM risk related to HT use.

Unlike these studies, in our present study in post-menopausal women, DM risk reduction related to current HT use during the follow-up was remarkable (62% for all current HT users during the follow-up) compared with never users. The great majority of the women, who used HT during follow-up of our study had started HT before baseline. This long-term HT exposure may partly explain the results of our study. Women who have used HT only in the past and may have stopped the use of HT before the follow-up may have lost part of its benefit, whereas women who have started HT use only a short time ago may not have yet reached the full benefit of it. Finnish women with an intact uterus mainly use oestradiol (OE2) combined with norethisterone acetate or levonorgesterel. Finnish women who have undergone hysterectomy use mainly OE2 only.

During menopause, women gain body fat in the abdominal region, and insulin sensitivity decreases (12, 13). These changes, along with dyslipidemia and hypertension, are consistent with the metabolic syndrome and predict DM2 (14) and coronary heart disease (15) in post-menopausal women. HT can have favorable effects on body fat distribution and could, therefore, act to reduce DM risk via this mechanism (16).

Several studies indicate that estrogen therapy may attenuate the accumulation of central fat in post-menopausal women (17–20). In the PEPI trial (21), less weight gain or increase in waist and hip circumferences were registered in women who received E + P therapy compared with placebo. Similarly, in the Danish osteoporosis prevention study (22), HT use seemed to have a weight-reducing effect.

There are several mechanisms other than effects on adiposity tissue and body fat distribution by which HT may be protective against DM. In a prospective study of older women not using HT, endogenous levels of bioavailable OE2 and testosterone were positively associated with levels of fasting glucose, insulin, and estimated insulin resistance, whereas only bioavailable testosterone predicted incident DM (23). Positive associations of bioavailable OE2 and testosterone with insulin resistance have also been observed in a cross-sectional study of untreated post-menopausal women (24). Low levels of sex hormone binding globulin are related negatively with obesity, insulin resistance, and incidence of DM in post-menopausal women (25–27). Hyperandrogenicity in women is closely associated with insulin resistance and risk factors for CVD and type 2 DM.

It has been hypothesized that estrogen may also have a direct effect on secretion of insulin by the pancreas. For example, estrogen receptors are present in pancreatic β-cells (28), and estrogen increases the release of insulin in β-cell culture models (29).

In conclusion, the present prospective cohort study indicates that HT use reduces the risk of DM in post-menopausal women. Further information on the role of HT, according to the route of administration and dose in modifying the risk of DM is needed.

Declaration of interest
None declared.

Funding
The authors would like to thank Kuopio University Hospital (EVO-grant), the Finnish Menopause Society (grant), the Academy of Finland (grant), National Statistics Finland, and the Finnish Social Insurance Institution for support of this work.
References


10. Diabetes Care

11. Diabetes Care

12. Diabetes Care

13. Diabetes Care

14. Diabetes Care

15. Diabetes Care

16. Diabetes Care

17. Diabetes Care

18. Diabetes Care

19. Diabetes Care

20. Diabetes Care

21. Diabetes Care

22. Diabetes Care

23. Diabetes Care

24. Diabetes Care

25. Diabetes Care

26. Diabetes Care

27. Diabetes Care

28. Diabetes Care

29. Diabetes Care

Received 18 March 2009
Accepted 23 March 2009

Hormone therapy protects from diabetes

www.eje-online.org